30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: Tornier

$76.7MM, +14% (U.S. $46.7MM, +15%; ex-U.S. $29.9MM, +13%)

Total Extremities $65.7MM, +14%

  • Upper $49.0MM, +20%
  • Lower $13.8MM, +2% (Ankle portfolio >20%)
  • Sports Med/Biologics $3.0MM, -4%

Large Joints/Other $10.8MM, +12%


  • Modest pricing pressure, -1%
  • Growth supported by Aequalis Ascend Flex shoulder, robust sales across ankle arthritis portfolio
  • Notes significant opportunity remaining for U.S. share gains with rollout of additional Ascend Flex sets, launch of Simpliciti (latter could claim $200MM-$250MM within 3-5 years of launch)
  • Pyrolytic carbon humeral head has positive feedback in limited ex-U.S. release
  • Completed planned transitions of U.S. salesforce to dedicated upper and lower extremity teams
  • Blueprint computer-aided surgical planning/glenoid placement tool now launched in select ex-U.S. regions; noting an increased mix shift to reverse shoulders
  • Rounding out ankle portfolio with TTC fusion plate, MedialMax dorsal fixation extension to lapidus system, Nitinol staples, compression screws, etc.
  • ~365 U.S. reps carrying Tornier products, with 165 direct reps; trained 50 reps in 3Q